| Literature DB >> 32752009 |
Cary F C Lam1, Melissa M Cadelis1, Brent R Copp1.
Abstract
The cytotoxic marine natural product class="Chemical">discorhabdin C contains aEntities:
Keywords: alkaloid; antimalarial; discorhabdin; discorhabdin dimer; electrophilic reactivity; marine natural product
Mesh:
Substances:
Year: 2020 PMID: 32752009 PMCID: PMC7460216 DOI: 10.3390/md18080404
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of natural products (+)-discorhabdin B (1) and C (2).
Figure 2Structure of the N-acetyl-l-cysteine adduct of (+)-discorhabdin B (3).
Figure 3Structures of the 1-pentanethiol 4 and N-acetyl-l-cysteine adducts 5 of discorhabdin C.
1H and 13C NMR data for compounds 4 and 5 in CD3OD (δ in ppm).
| No. | 4 | No. | 5 | ||
|---|---|---|---|---|---|
| δH (Mult., | δC b | δH (Mult., | δC d | ||
| 1 | - | 169.7 | - | 167.5 | |
| 2 | 6.41 (s) | 121.7 | 6.56/6.58 (s) | 122.2/122.4 | |
| 3 | - | 176.2 | - | 176.2 | |
| 4 | - | 125.9 | - | 126.0 | |
| 5 | 7.72 (s) | 152.1 | 7.71 (s) | 152.2 | |
| 6 | 47.3 | 47.3 | |||
| 7 | 2.39–2.33 (m) | 39.2/39.4 | 2.34 (m) | 39.2/39.4 | |
| 2.16–2.12 (m) | 2.13 (m) | ||||
| 8 | 3.92–3.87 (m) | 39.2/39.4 | 3.88 (m) | 39.2/39.4 | |
| 3.73–3.67 (m) | 3.69 (m) | ||||
| 10 | - | 154.1 | - | 154.2 | |
| 11 | - | 166.4 | - | 166.4 | |
| 12 | - | 125.3 | - | 125.4 | |
| 14 | 7.21 (s) | 127.9 | 7.20 (s) | 127.9 | |
| 15 | 121.4 | - | 121.5 | ||
| 16 | 2.95–2.83 (m) | 19.6 | 2.89 (m) | 19.5 | |
| 17 | 3.79 (t, 7.4) | 45.2 | 3.84–3.76 (m) | 45.3/45.4 | |
| 19 | - | 156.2 | - | 156.1 | |
| 20 | - | 94.8 | - | 94.3 | |
| 21 | - | 124.6 | - | 124.6 | |
|
|
| ||||
| 2’ | 3.03–2.95 (m) | 32.2/32.5 | 2′ | 3.54/3.57 (m) | 33.8/34.2 |
| 3’ | 1.75–1.69 (m) | 28.4 | 3.21/3.27 (m) | ||
| 4’ | 1.47–1.33 (m) | 32.2/32.5 | 3′ | 4.71/4.75 (m) | 51.5/52.0 |
| 5’ | 1.47–1.33 (m) | 23.2 | 5′ | - | 173.5 |
| 6’ | 0.92 (t, 7.2) | 14.2 | 6′ | 1.94/1.97 (s) | 22.4 |
| 7′ | - | 168.1 |
a 500 MHz for 1H NMR; b 125 MHz for 13C NMR; c 600 MHz for 1H NMR; d 100 MHz for 13C NMR.
1H (400 MHz) and 13C (100 MHz) NMR data for compound 6 in D2O (δ in ppm) a.
| No. | δH (Mult., | δC |
|---|---|---|
| 1 | 4.28 (d, 2.3) | 55.3 |
| 2 | 4.38 (d, 2.3) | 66.7 |
| 3 | - | 98.0 |
| 4 | 4.42 (d, 3.4) | 57.5 |
| 5 | 4.15 (br m) | 75.8 |
| 6 | 41.7 | |
| 7 | 2.53 (d, 14.0) | 25.0 |
| 1.74 (m) | ||
| 8 | 3.90 (dd, 14.0, 4.3) | 40.5 |
| 3.62 (m) | ||
| 10 | - | 155.2 |
| 11 | - | 168.2 |
| 12 | - | 126.0 |
| 14 | 7.22 (s) | 131.0 |
| 15 | 122.1 | |
| 16 | 3.04 (m) | 22.2 |
| 17 | 4.22 (m) | 55.4 |
| 4.06 (m) | ||
| 19 | - | 154.2 |
| 20 | - | 92.0 |
| 21 | - | 125.7 |
| 2’ | 3.19 (t, 8.0) | 50.5 |
| 3’ | 1.74 (m) | 27.4 |
| 4’ | 1.34 (m) | 30.6 |
| 5’ | 1.34 (m) | 24.2 |
| 6’ | 0.88 (m) | 15.7 |
a External reference to dioxane (δH 3.75; δC 69.3).
Figure 4Structure of aminopentane discorhabdin C dihydrate adduct 6.
Figure 5PCModel optimised dominant chair conformers of diastereomers 1S*,2S*,4S*,5R*,6R*-6 (A) and 1S*,2S*,4R*,5R*,6R*-6 (B) with key NOE correlations observed (right).
1H (400 MHz) and 13C (100 MHz) NMR data for compound 7 in CD3OD (δ in ppm).
| No. | δH (Mult., | δC |
|---|---|---|
| 1 | 1.85 (t, 7.2) | 33.8 |
| 2 | 2.28–2.14 (m) | 35.9 |
| 3 | - | 92.0 |
| 4 | 2.28–2.14 (m) | 35.9 |
| 5 | 1.85 (t, 7.2) | 33.8 |
| 6 | - | 35.1 |
| 7 | 1.68 (t, 5.5) | 36.2 |
| 8 | 3.46 (t, 5.5) | 39.1 |
| 10 | - | 151.4 |
| 11 | - | 167.7 |
| 12 | - | 124.8 |
| 14 | 7.10 (s) | 126.5 |
| 15 | - | 121.2 |
| 16 | 2.91 (t, 7.1) | 21.1 |
| 17 | 4.15 (t, 7.1) | 45.8 |
| 19 | - | 157.1 |
| 20 | - | 106.4 |
| 21 | - | 125.4 |
Figure 6Structure of carbinolamine analogue of discorhabdin C 7 (left) and key HMBC correlations supporting the ring-closed structure (right).
1H (400 MHz) and 13C (100 MHz) NMR data for compound 8 (δ in ppm).
| No. | δH (Mult., | δC b | No. | δH (Mult., | δC b |
|---|---|---|---|---|---|
| 1 | 7.81 (s) | 156.0 | 1’ | 6.44 (d, 2.0) | 54.1 |
| 2 | - | 124.9 | 2’ | 4.29 (d, 2.0) | 71.2 |
| 3 | - | 177.0 | 3’ | - | 98.4 |
| 4 | - | 124.9 | 4’ | Obscured | 58.6 |
| 5 | 7.81 (s) | 156.0 | 5’ | 4.16 (br m) | 76.0 |
| 6 | - | 47.7 | 6’ | - | 42.8 |
| 7 | 2.15 (t, 5.5) | 35.3 | 7’ | 2.31 (dd, 13.5, 2.4) | 24.3 |
| 8 | 3.76 (m) | 41.1 | 1.07 (td, 13.5, 5.4) | ||
| 10 | - | 154.9 | 8’ | 3.89 (m) | 40.6 |
| 11 | - | 169.6 | 3.56 (m) | ||
| 12 | - | 126.6 | 10’ | - | 154.9 |
| 14 | 6.86 (s) | 130.1 | 11’ | - | 168.8 |
| 15 | - | 124.5 | 12’ | - | 125.5/126.2 |
| 16 | 2.72 (m) | 20.7 | 14’ | 7.24 (s) | 130.8 |
| 17 | 3.89 (m) | 46.6 | 15’ | - | 122.3 |
| 19 | - | 156.5 | 16’ | 3.06 (m) | 22.2 |
| 20 | - | 93.7/94.0 | 17’ | 4.13 (m) | 55.4 |
| 21 | - | 126.6 | 4.04 (m) | ||
| 19’ | - | 154.2 | |||
| 20’ | - | 93.7/94.0 | |||
| 21’ | - | 125.5/126.2 |
a D2O; b 90% H2O + 10% D2O. Both sets of data externally reference to dioxane (δH 3.75; δC 69.3).
Figure 7The structure of discorhabdin C dimer (8) (left) and key intra- (H-1′/H-7′β, H-5′/H-8′β) and inter-fragment (between H-14 (of fragment A) and H-17′α, H-2′ and H-7′α (of fragment B)) NOESY correlations (right) observed.
In vitro antitumour activities (μM) of discorhabdin C (2) and thiopentanyl analogue 4.
| Compound (NSC) 1 | GI50 2 | TGI 2 | LC50 2 |
|---|---|---|---|
| 0.13 | 0.36 | 2.3 | |
| 1.4 | 3.9 | 10.5 |
1 NSC number is the NCI reference number for each compound. Search for this number at http://dtp.cancer.gov to view complete information of all in vitro assay profiles; 2 GI50 (50% growth inhibition), TGI (total growth inhibition) and LC50 (50% cell kill) data are averaged calculated mean micro-molar values obtained from two experiments at the NCI.
Figure 8Structures of additional discorhabdin natural product and semi-synthetic analogues 9–17 that were evaluated for antiparasitic and cytotoxic properties.
Anti-protozoal and cytotoxic activities of discorhabdin natural products and semisynthetic analogues 1, 2, 6–17.
| Compd. |
|
|
| L6 f | SI | |
|---|---|---|---|---|---|---|
|
| 99% (1.5) | 100% (1.5) | 57% (1.5) | 100% (1.5) | n.t. h | - |
|
| 99% (1.4) | 100% (1.4) | 47% (1.4) | 100% (1.4) | n.t. | - |
|
| n.t. | n.t. | n.t. | 0.25 | 0.81 | 3.2 |
|
| n.t. | n.t. | n.t. | 0.09 | 1.7 | 19 |
|
| 0.71 | 11.1 | 18.7 | 6.4 | 2.1 | 0.3 |
|
| n.t. | n.t. | n.t. | 0.40 | 0.11 | 0.3 |
|
| 99% (1.8) | 100% (1.8) | 75% (1.8) | 100% (1.8) | n.t. | - |
|
| 1.4 | 29 | 64 | 1.6 | 9.1 | 5.7 |
|
| 2.3 | 63 | 94 | 12 | 17 | 1.4 |
|
| 0.40 | 3.6 | 7.2 | 0.03 | 1.1 | 37 |
|
| 1.3 | 9% (12) | 20% (1.9) | 20% (1.9) | 11 | - |
|
| 100% (1.5) | 100% (1.5) | 97% (1.5) | 100% (1.5) | n.t. | - |
|
| n.t. | n.t. | n.t. | 1.7 | 6.1 | 3.6 |
|
| 0.33 | 0% (0.8) | 29% (0.8) | 0.08 | 41 | 510 |
a IC50 values in μM, or % inhibition at the μM dose stated. All data is the mean value from duplicate assays; b Trypanosoma brucei rhodesiense (positive control melarsoprol, IC50 0.01 μM); c Trypanosoma cruzi (positive control benznidazole, IC50 1.35 μM); d Leishmania donovani (positive control miltefosine, IC50 0.52 μM); e Plasmodium falciparum, K1 strain (positive control chloroquine, IC50 0.20 μM); f L6 rat skeletal myoblast cell line for cytotoxicity (positive control podophyllotoxin, IC50 0.01 μM); g Antiplasmodial selectivity index = L6 IC50/P f. IC50; h Not tested.
Figure 9Summary of electrophilic reactivity/cytotoxicity observed for discorhabdin B (1) [16] and discorhabdin C (2) and cyclic carbinolamine derivative (7) (present study).